Insider Selling: Insmed, Inc. (NASDAQ:INSM) CEO Sells 6,830 Shares of Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 6,830 shares of the business's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $102.37, for a total transaction of $699,187.10. Following the completion of the sale, the chief executive officer owned 233,924 shares of the company's stock, valued at $23,946,799.88. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

William Lewis also recently made the following trade(s):

• On Monday, June 16th, William Lewis sold 129,805 shares of Insmed stock. The shares were sold at an average price of $100.39, for a total transaction of $13,031,123.95.
• On Tuesday, June 3rd, William Lewis sold 5,472 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total transaction of $391,248.00.
• On Monday, June 2nd, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $71.31, for a total transaction of $487,047.30.
• On Tuesday, May 20th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $67.72, for a total value of $462,527.60.
• On Tuesday, May 20th, William Lewis sold 21,057 shares of Insmed stock. The stock was sold at an average price of $67.65, for a total transaction of $1,424,506.05.
• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total transaction of $247,415.31.
• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The shares were sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $72.57, for a total value of $495,653.10.

Insmed Price Performance

Insmed stock traded down $1.28 during midday trading on Friday, reaching $102.89. The company's stock had a trading volume of 550,758 shares, compared to its average volume of 2,293,685. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $106.83. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The business has a 50-day moving average price of $86.18 and a 200-day moving average price of $78.27. The stock has a market cap of $19.52 billion, a PE ratio of -17.30 and a beta of 0.90.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business's revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.06) earnings per share. On average, sell-side analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Bank of America lifted their target price on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Morgan Stanley lifted their target price on Insmed from $102.00 to $108.00 and gave the stock an "overweight" rating in a report on Thursday. UBS Group dropped their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. Finally, Mizuho boosted their price target on Insmed from $96.00 to $110.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus target price of $108.47.

Institutional Trading of Insmed

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Darwin Global Management Ltd. lifted its stake in shares of Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after acquiring an additional 2,463,261 shares during the period. Norges Bank bought a new position in shares of Insmed during the 4th quarter worth approximately $126,606,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after purchasing an additional 1,799,382 shares in the last quarter. Nuveen LLC bought a new position in shares of Insmed in the 1st quarter worth $88,351,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.